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MHC class I molecules present endogenous 
peptides to CTLs. Many of these peptides are 
generated by the proteasome from newly syn-
thesized but rapidly degraded proteins called 
rapidly degraded proteins (RDPs) or defective 
ribosomal products (1, 2). The proteasome pro-
ducts are trimmed by tripeptidyl peptidase II 
(3) and downstream peptidases, and only a small 
fraction will escape complete degradation by 
binding the transporter associated with anti-
gen processing (TAP) (4–6). TAP translocates 
peptides into the ER lumen for further trim-
ming and binding to MHC class I molecules 
(7). Upon peptide binding, the MHC class I 
molecules traffi   c to the cell membrane, allow-
ing T cells to examine the intracellular peptide 
content and eliminate those cells presenting 
foreign peptides. TAP is not fully active under 
normal circumstances, as the peptide pool forms 
the limiting factor in the antigen presentation 
pathway (7). This may change under stressful 
conditions. For example, during an acute 
  infl   uenza infection the generation of viral 
  proteins leads to a rapid increase in peptide 
generation enabling swift CTL responses to the 
infection (1). Here we have examined the ef-
fect on the intracellular peptide products and 
MHC class I expression of another clinically 
relevant condition—irradiation.
The best-known eff  ect of ionizing radiation 
is the induction of double-stranded DNA 
breaks, which can result in mutations leading to 
transformation and tumor formation if DNA 
repair fails (8, 9). Cells respond to DNA damage 
by activating complex pathways to arrest the 
cell cycle, allowing DNA repair, or inducing 
programmed cell death (10). Microarray   analysis 
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of cells after ionizing radiation has revealed up-regulation of 
nucleotide excision repair genes, cell cycle genes, and genes 
involved in apoptosis (11). In addition, irradiation-induced 
radical formation modifi  es proteins by radical-induced cross-
linking, breakage of disulphide bonds, and amino acid side-
chain oxidation (12), which may result in protein unfolding 
and degradation. Absorption of radiation can occur directly 
within proteins but mostly causes radiolysis of water, which 
constitutes up to 90% of the volume of cells. The resulting 
short-living radicals can modify intracellular proteins and 
DNA. It is unknown if γ-  irradiation modifi  es the intracellular 
protein pool in vivo and whether the resulting MHC class I 
peptide repertoire is altered by this treatment. We show that 
γ-irradiation enhanced peptide production and surface ex-
pression of MHC class I for many days at higher doses. In 
  addition, the MHC class I peptide repertoire now includes 
  radiation-specifi  c peptides. The radiation-induced eff  ects on 
MHC class I antigen presentation may have important conse-
quences because combining radiotherapy with immunother-
apy results in superior antitumor responses.
RESULTS
Ionizing radiation enhances surface expression of MHC 
class I molecules
The antigen presentation pathway is far from saturated under 
normal conditions, and changes in the intracellular protein 
pool will induce rapid changes in peptide–MHC class I com-
plexes, enabling the immune system to respond swiftly to 
changes in the intracellular protein content (1, 13). Ionizing 
radiation is known to induce radicals, which oxidize proteins 
and DNA, resulting in a plethora of biological eff  ects. We 
exposed the human melanoma cell line MelJuSo to diff  erent 
doses of γ-radiation, and 18 h later quantifi  ed cell surface–
MHC class I complexes by fl  ow cytometry. Consistent with 
previous reports (14–16), we observed a radiation-induced 
increase in MHC class I expression in vitro. This increase was 
dose dependent (Fig. 1 A), whereas the expression of another 
protein, the transferrin receptor, remained unaff  ected. Iden-
tical increases were observed after γ-irradiation of transfected 
MelJuSo cells expressing HLA-A2 under the control of the 
CMV promoter, indicating that the increase in HLA expres-
sion was not caused by transcriptional activation of the MHC 
locus (unpublished data).
To test the temporal eff  ect of radiation on MHC class I 
expression, MelJuSo cells were irradiated with diff  erent doses 
and cultured for various times before analysis of MHC class I 
expression by FACS (Fig. 1 B). A marked increase in MHC 
class I expression was observed at higher doses (10–25 Gy) 
over a period of 3 d. To test whether similar increases in 
MHC class I expression could be observed in vivo, we irradi-
ated HLA-A2 transgenic mice (17), such that one kidney was 
outside and the other kidney in the fi  eld of radiation with 
a dose of 25 Gy. 24 h after irradiation, kidneys were isolated 
and sections of the respective kidneys were stained with anti-
bodies against human MHC class I H chains (Fig. 1 C). 
Quantifi  cation of fl  uorescence revealed a two- to threefold 
increase in HLA expression in the irradiated kidney com-
pared with the nonirradiated kidney, similar to the eff  ects in 
tissue culture (Fig. 1, A and B). MHC class I levels also in-
creased in subcutaneous tissues of transgenic mice upon irra-
diation (unpublished data). Thus, γ-radiation results in a 
dose-dependent cellular response by increasing MHC class I 
expression in vitro as well as in vivo.
Radiation expands the intracellular peptide pool 
in a dose-dependent manner
To understand the molecular basis for radiation-induced 
MHC class I expression, we analyzed quantitative changes in 
the intracellular peptide pool by a TAP mobility assay using 
MelJuSo cells stably transfected with TAP1-GFP. The lateral 
mobility of the TAP transporter tagged with the GFP can 
be followed using a time-lapse protocol visualizing fl  uores-
cence recovery after photobleaching (FRAP). TAP transports 
  peptides into the ER in an ATP-dependent manner, and its 
activity is inversely related to its mobility. Fully active TAP 
transporters diff   use at a slow rate (possibly caused by the 
opened pore), whereas inactive TAP molecules (in a closed 
conformation) diff  use more rapidly (1). The diff  usion rate of 
TAP transporters in nonirradiated cells is increased in cells de-
pleted for peptides (after proteasome inhibition) and decreased 
in peptide-saturated cells (Fig. 2 A). When cells were irradi-
ated with a dose of 4 Gy and assayed 1 h later, TAP mobility 
decreased to levels comparable to peptide-saturated cells. This 
was dependent both on proteasomal activity and ATP. ATP 
depletion increased TAP mobility in irradiated cells to a level 
similar to ATP-depleted control cells (Fig. 2 A). The human 
CMV protein US6 inhibits and arrests conformational changes 
in TAP (18, 19). Ionizing radiation did not alter the mobility 
of TAP in cells transfected with the ER luminal part of US6 
(Fig. 2 B). This excludes possible eff  ects of irradiation on TAP 
mobility caused by alterations in the ER membrane, indicat-
ing that irradiated cells have an increased TAP activity be-
cause of higher levels of intracellular peptides.
An increase in peptide levels could be the result of re-
duced peptidase activity; therefore, we tested whether pepti-
dase activity was inhibited by γ-irradiation by introducing 
internally quenched fl  uorescent peptides in control cells or 
cells 2–3 h after radiation by 25 Gy. These peptides will be-
come fl  uorescent after degradation by intracellular peptidases 
(3, 4). We determined the stability of peptides of diff  erent 
length, including a 9- and 14-mer peptide, and a 27-mer tri-
peptidyl peptidase II substrate (Fig. 2 C). No substantial dif-
ference in the half-life of these peptides was observed after 
irradiation. If any, the peptide half-life was shorter in cells 
exposed to γ-irradiation. This suggests that the increase in 
TAP activity and MHC class I expression does not result 
from inactivation or saturation of intracellular peptidase ac-
tivity, but from an increase in protein degradation in response 
to ionizing radiation.
To independently validate increased protein turn-over in 
response to γ-radiation, MelJuSo cells were exposed to diff  -
erent doses of γ-radiation and the extent of polyubiquitination JEM VOL. 203, May 15, 2006  1261
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determined 1 or 6 h later by Western blotting with antiubiq-
uitin antibodies (Fig. 2 D). Because any eff  ect on polyubiq-
uitination may be quenched by enhanced proteasomal 
degradation, the proteasome was inhibited by MG132 30 
min before cell lysis. Increased polyubiquitination is observed 
in response to radiation. The Western blot was quantifi  ed by 
luminescence detection and the polyubiquitin signal (Fig. 2 D, 
vertical line) related to   input protein. The relative lumines-
cence visualizes an increase in polyubiquitinated species only 
after proteasome inhibition (Fig. 2 D, right), indicating 
  radiation-enhanced protein ubiquitination followed by protea-
somal degradation. This should result in more degradation 
fragments as detected in the experiments directly measuring 
TAP   activity (Fig. 2, A–C).
Figure 1.  Ionizing radiation increases the expression of peptide–
MHC class I complexes at the cell surface. (A) Cells were exposed 
to different doses of irradiation as indicated, and levels of peptide–
MHC class I complexes at the cell surface were measured 18 h after 
γ-irradiation by fl  ow cytometry. Fluorescence in the absence of the 
fi  rst antibody (W6/32) is indicated (background). (Inset) The mean 
 fl uorescence intensity (MFI) plotted for MHC class I as well as the 
transferrin receptor (TfR) after an 18 h culture after various doses of 
γ-irradiation (representative experiment). (B) Time course of radiation-
induced MHC class I up-regulation. MelJuSo cells were exposed to 
various doses of γ-radiation and cultured for the indicated times 
  before analysis of surface MHC class I expression by FACS. The MFI 
was determined and related to MHC class I expression in control 
MelJuSo cells, and the ratio was plotted. Marked long-term increases 
in MHC class I expression are observed at higher doses of radiation. 
(C) An HLA-A2 transgenic mouse was locally exposed to γ-irradiation 
at a dose of 25 Gy. 24 h later, the mouse was killed and sections of a 
kidney exposed to γ-irradiation and a kidney outside the radiation 
fi  eld were stained with a rabbit anti–MHC class I H chain serum 
  followed by a secondary antibody coupled to Cy5. Background fl  uores-
cence was detected with the second antibody only. Images were made 
under identical settings.1262  RADIATION AND MHC CLASS I PRESENTATION | Reits et al.
Figure 2.  Ionizing radiation increases intracellular peptide levels in 
a dose-dependent manner. (A) TAP activity (which correlates with the 
amount of intracellular peptides) was measured through its lateral mobil-
ity in the ER membrane using FRAP. Lactacystin was used to deplete cells 
for peptides by inhibiting the proteasome. ATP depletion and proteasome 
inhibition inactivate TAP. Cycloheximide was used to inhibit protein 
  synthesis. TAP activity was measured 1 h after a dose of 4 Gy. (n = 9; 
mean ± SD). (B) TAP activity measured 1–2 h after different exposures to 
γ-irradiation as indicated (n = 9; mean ± SD). (C) Control cells and cells 
exposed to 25 Gy radiation were microinjected with peptide substrates of JEM VOL. 203, May 15, 2006  1263
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Because MHC class I expression increased in a radiation 
dose-dependent manner (Fig. 1 A), we investigated whether 
the peptide pool increased similarly. Cells were irradiated 
with an increasing dose of γ-irradiation, and TAP mobility 
was determined. All cells show peptide-saturated levels at 1 h 
after irradiation (Fig. 2 B), which does not explain the dose-
dependent increase in MHC class I expression. Therefore we 
tested the temporal eff  ects of diff  erent doses of γ-radiation 
on the intracellular peptide pool, again using the TAP mo-
bility assay (Fig. 2 E). The increase in TAP activity lasted 
only 1 h when cells were irradiated with 1 Gy. A dose of 
4 Gy resulted in peptide-saturated levels for around 3 h be-
fore the cells returned to nonsaturated levels, whereas pep-
tide saturation occurred for up to 7 h in cells irradiated with 
7 Gy. Cells irradiated with 25 Gy remained peptide saturated 
for more than 24 h (Fig. 2 E, lower line). These kinetics may 
explain the dose-dependent eff  ect of irradiation on MHC 
class I expression.
Protein degradation and synthesis after irradiation
To test whether stable proteins or RDPs contributed to the 
increased intracellular peptide pool, cells were pretreated with 
the translation inhibitor cycloheximide before irradiation to 
inhibit protein synthesis during and after irradiation. RDPs 
are defi  ned as translation products that failed to become func-
tional and are rapidly degraded after translation (5, 7). This 
pool is immediately aff  ected by translation inhibition unlike 
the stable protein pool (1, 2). In contrast to nonirradiated 
cells, treatment with cycloheximide had no eff  ect on TAP 
activity, indicating that irradiation induces the degradation 
of stable proteins (Fig. 2 A). To visualize the breakdown of 
proteins after irradiation, we stably expressed enhanced GFP 
(EGFP) under the CMV promotor in MelJuSo cells. Cells 
were irradiated at 25 Gy, and GFP fl  uorescence was com-
pared with control cells by fl  ow cytometry. Fluorescence did 
not decrease in cells 4 h after irradiation (when GFP would 
have been degraded), probably because the aff  ected protein 
pool is too small to detect directly by FACS. Surprising, GFP 
fl  uorescence increased in cells 24 h after irradiation (Fig. 3 A). 
The apparent increase in protein expression after irradiation 
may be caused by increased rates of protein translation after 
radiation-induced activation of the kinase mammalian target 
of rapamycin (mTOR), a critical regulator of protein transla-
tion (20). mTOR activates S6K which releases the initiation 
factor 4E-binding protein 1, resulting in enhanced ribosomal 
translation. As the name indicates, mTOR can be specifi  cally 
inhibited by the drug rapamycin (21). When GFP-expressing 
MelJuSo cells were irradiated in the presence of rapamycin, 
no increase in GFP expression in response to ionizing radia-
tion was observed, suggesting that the mTOR pathway plays 
a critical role in the responses to irradiation (Fig. 3 A). Rapa-
mycin also decreased GFP expression in nonirradiated cells, 
suggesting that mTOR activity is also required for optimal 
protein expression under control conditions.
To measure the eff  ect of radiation-induced activation 
of the mTOR pathway on the intracellular peptide pool, 
MelJuSo cells were irradiated with a dose of 25 Gy and cul-
tured for 24 h. The increased peptide pool was sensitive to 
rapamycin treatment as deduced from TAP activity mea-
surements by FRAP, and also to cycloheximide when added 
during the last hour of the culturing period (Fig. 3 B). This 
is in contrast with the initial increase in intracellular pep-
tides that was not inhibited by treatment with cyclohexi-
mide or rapamycin, when measured 1 h after irradiation 
(Fig. 2 A; unpublished data). This suggests that after the ini-
tial phase of breakdown of existing proteins, protein synthe-
sis increased because of mTOR activation resulting in higher 
levels of (RDP-derived) peptides. To determine the contri-
bution of mTOR activation by irradiation on enhanced 
MHC class I expression, cells were exposed to 25 Gy fol-
lowed by a further culture for 4 or 24 h in the absence or 
presence of rapamycin. No eff  ect of rapamycin on MHC 
class I expression was observed after 4 h, but the radiation-
induced increase in MHC class I expression 24 h after irra-
diation was markedly reduced when cells were treated with 
rapamycin (Fig. 3 C). This indicates that mTOR activation 
is important in the later phase of the radiation-induced en-
hanced MHC class I presentation.
To test whether the radiation-induced mTOR pathway 
also enhanced translation of MHC class I molecules, HLA-
A2-GFP–expressing MelJuSo cells were biosynthetically la-
beled 6 h after exposure to 10 or 20 Gy radiation. To assess 
the role of the mTOR pathway, cells were cultured in the 
presence or absence of the inhibitor rapamycin. Because ra-
dioactive labeling after amino acid starvation will activate the 
mTOR pathway, we added 35S-methionine/cystein to the 
normal culture medium for 1 h before lysis and isolation of 
MHC class I complexes, free H chains, and MHC class II 
  molecules (Fig. 3 D). Translation of GFP-tagged and endog-
enous MHC class I molecules, H chains as well as MHC class II
different length (as indicated) and the half-life was determined (n = 8; 
mean ± SD). (D) (Left) MelJuSo cells are exposed to various doses of 
γ-radiation followed by a culture for 1 or 6 h, as indicated. In the last 
30 min, cells were cultured in the presence or absence of the proteasome 
inhibitor MG132 to visualize the polyubiquitinated species produced but 
not converted by the proteasome. N-ethylmaleimide was added before 
lysis to inhibit deubiquitinating enzymes, and cell lysates were separated 
by 10% SDS-PAGE and transferred to polyvinylidene fl  ouride membranes 
for detection of ubiquitin with antibody FK2. The position of the marker 
proteins is indicated and the polyubiquitinated protein fraction quantifi  ed 
indicated by a bar (marked with an asterisk) on the right site of the gel. 
(Right) Quantifi  cation of the effects of radiation on polyubiquitination. 
The luminescence for the polyubiquitin pool (area indicated by an aster-
isk) of the Western blot was quantifi  ed, corrected for protein input, and 
related to the signal in the control cells. A marked increase in the polyu-
biquitin pool is observed after radiation when proteasomes are inhibited 
by MG132. (E) TAP activity measured over time after γ-irradiation at time 
point t = 0. The top line indicates TAP activity in nonirradiated cells; the 
bottom line indicates TAP activity in peptide saturated cells (each data 
point n > 3; mean ± SD). 1264  RADIATION AND MHC CLASS I PRESENTATION | Reits et al.
Figure 3.  The mTOR pathway, ionizing radiation, and antigen pre-
sentation by MHC class I. (A) MelJuSo cells stably expressing GFP under 
the control of the CMV promoter were exposed to 25 Gy γ-irradiation 
in the presence or absence of the mTOR inhibitor rapamycin. GFP 
  expression was determined by fl  ow cytometry at 0, 4, or 24 h after 
γ-irradiation (n = 6; mean ± SD). (B) MelJuSo cells expressing TAP1-GFP 
were exposed to 25 Gy radiation and cultured for 24 h before analysis. 
Rapamycin was either present during the 24 h culture period or only 
during the last 3 h. Alternatively, translation was inhibited by cyclohexi-
mide added during the last hour before analysis. The intracellular peptide 
pool was detected by FRAP. (C) MelJuSo cells were exposed to 25 Gy 
radiation in the presence or absence of the mTOR inhibitor rapamycin JEM VOL. 203, May 15, 2006  1265
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molecules was not altered in response to radiation but was 
still inhibited by rapamycin and thus aff  ected by constitutive 
mTOR activity.
Radiation generates unique MHC class I binding 
antigenic peptides
The increased pool of MHC class I molecules after irradia-
tion may be loaded with similar peptides as nonirradiated 
cells, or with a unique set of peptides generated in response 
to radiation-induced mTOR-enhanced translation and de 
novo protein production. To analyze the peptide profi  le af-
ter ionizing radiation, MHC class I molecules were purifi  ed 
from control cells and cells 18 h after irradiation with 25 Gy. 
Peptides were eluted and separated into 50 fractions by 
  reverse phase HPLC (rpHPLC). Each fraction isolated from 
the radiated cells was analyzed by mass spectometry (MS) 
and compared with the peptide content in the corresponding 
fraction of control cells (Fig. 4 A). Comparison of respective 
fractions revealed  1% unique peptides in irradiated cells, 
implying that the majority of the peptides presented after 
irradiation were derived from proteins also expressed and de-
graded in control cells. Several peptides that were unique to 
the irradiated peptide pool were sequenced by tandem MS/
MS analysis (Fig. 4 B). All peptides have the correct anchor 
residues for binding to HLA-A1 molecules of MelJuSo cells 
(Fig. 4 B, bold) (22). Two peptides are derived from pro-
teins involved in DNA repair (MSH6 and PCNA [23]), one 
in protein breakdown (nuclear F-box protein Fbl7 involved 
in the recognition and ubiquitin tagging of [unknown] sub-
strates) and one protein (CGI 51 or SAM50) that is located 
at the outer mitochondrial membrane (unpublished data) and 
probably part of the mitochondrial protein import system 
(24). These peptides are derived from proteins most likely 
up-regulated in response to γ-irradiation.
The identifi  cation of radiation-induced peptides on irra-
diated tumor cells may allow a combination of radiotherapy 
and immunotherapy to induce specifi  c responses, providing 
that T cells recognize some of these uniquely expressed pep-
tides. To identify CTLs recognizing these peptides, HLA-A1 
tetramers were generated and loaded with radiation-induced 
peptides CGI 51(206–215), MSH6(469–478), and F-box protein 
Fbl7(335–362) (Fig. 4 B). Two out of three healthy HLA-A1–
positive donors had a small population ( 0.08%) of tetramer-
reactive CD8+ T lymphocytes when PBMCs were incubated 
with tetramers containing one of the three peptides (Fig. 4 C). 
Infl  uenza-specifi  c T cells could be detected in all three 
donors ( 0.14%) using HLA-A1 tetramers containing infl  u-
enza virus peptide, whereas no reactivity (<0.02%) was found 
with HLA-A1 tetramers loaded with peptide derived from 
the melanoma-associated antigen MAGE-A1 (25), which is 
not expressed in normal HLA class I–expressing tissues (unpub-
lished data). When CD8+ T cells were isolated from donor 
lymphoid cells and stimulated for 1 wk with CD8-negative 
lymphoid cells that were preloaded with radiation-induced 
peptides, the percentage of tetramer-binding T cells did not 
increase in these cultures, despite the presence of radiation-
induced antigen-specifi  c T cells in two of these donors. It is 
possible that CTL specifi  c for radiation-induced peptides are 
“anergic” as has been shown for Mart-1/HLA-A2–specifi  c 
CTL in both healthy donors and patients (26, 27). These 
T cells have to be stimulated more extensively to leave their 
“anergic state” before becoming responsive to radiation-
  induced cells, a phenomenon which has frequently been ob-
served in tumor vaccination studies (28).
Irradiation of tumor cells enhances T cell recognition 
in vitro and boosts the effi  cacy of adoptive CTL 
immunotherapy in vivo
To test if the radiation-induced up-regulation of MHC class I 
results in better recognition of target cells, we irradiated 
mouse colon adenocarcinoma MC38 cells (20 Gy) that ex-
press the tumor antigen gp70. The eff  ect of radiation and the 
mTOR-dependent MHC class I expression was determined. 
Similar to MelJuSo cells, MC38 cells up-regulate MHC class I 
expression upon irradiation, which can be inhibited by ra-
pamycin (Fig. 5, A–D). Subsequently the manipulation of 
recognition of the gp70 epitope on cells by specifi  c CTL was 
tested. Irradiation of MC38 cells leads to enhanced lysis in a 
rapamycin-dependent fashion (Fig. 5 E). Rapamycin had no 
eff  ect on CTL recognition of (nonirradiated) cells. This sug-
gests that the radiation-induced increase in MHC class I ex-
pression leads to increased sensitivity to antigen-specifi  c 
cytotoxic T cell killing.
To examine if this phenomenon also occurs in vivo, we 
fi  rst tested the temporal eff  ect of radiation on expression of 
H2-Kb molecules. MC38 cells were exposed to various doses 
of radiation, followed by culture and FACS analyses for 
H2-Kb molecules (Fig. 5 F). MHC class I expression is increased 
for over 11 d after 8 or 10 Gy radiation. To then test the ef-
fects of radiation on antitumor immune responses, we used 
an adoptive transfer paradigm. MC38 cells were injected sub-
cutaneous at the right hind leg of C57/BL6 mice. After 9 d, 
mice were divided into four groups that received either no 
treatment, 10Gy radiation of the tumor tissue, only adoptive 
transfer of CTL, or the combination of irradiation of the tu-
mor, followed 24 h later by transfer of CTL. Tumors of mice 
that did not receive any treatment (Fig. 5 G) grew progres-
sively, ultimately causing the death of the animals (100% by 
before labeling the cells with the MHC class I antibody W6/32 for fl  ow 
cytometric analysis. (n = 4; mean ± SD). (D) MelJuSo cells stably express-
ing HLA-A2/GFP under control of the CMV promoter were radiated at the 
doses indicated and cultured for another 6 h in the presence or absence 
of rapamycin, as indicated. Cells were labeled with 35S-methionine/cys-
tein 60 min before lysis, and endogenous and GFP-tagged MHC class I 
molecules, MHC class II molecules, and the free MHC class I H-chains 
were isolated, as indicated. The position of the molecules as well as the 
marker proteins on the 10% gel is indicated. NRS, normal rabbit serum 
control immunoprecipitation. (Right) Quantitation of the SDS-PAGE sig-
nals related to that from nonradiated control cells after subtraction of 
the same Mr area in the NRS lane.1266  RADIATION AND MHC CLASS I PRESENTATION | Reits et al.
day 30). Exposure of tumors to irradiation at day 9 reduced 
tumor outgrowth only, and treatment of tumors with adop-
tively transferred gp70-specifi  c CTL at day 10 did not signifi  -
cantly inhibit tumor outgrowth as well. However, treatment 
of tumors with the combination of irradiation and CTL 
adoptive transfer, markedly inhibited tumor outgrowth (P < 
0.001 vs. no treatment; P < 0.001 vs. irradiation alone; P < 
0.001 vs. adoptive transfer alone). Moreover, 62.5% of the 
mice treated with this combination of tumor irradiation and 
CTL adoptive transfer resolved their tumor and became tu-
mor-free during the experiment, suggesting that radiotherapy 
is an important supplement to current anticancer immuno-
therapy protocols.
DISCUSSION
Radiotherapy is—after surgery—the most successful cancer 
treatment. Besides its cytotoxic properties, radiation can in-
duce multiple eff  ects on cells and tissues as a function of 
  dosage. In animal models and clinical studies, lower doses of 
radiation may induce immunomodulatory activities by up-
regulating tumor-associated antigens (29, 30), adhesion mol-
ecules (31, 32) and IFN-γ secretion (33, 34), and CTL may 
be attracted to irradiated tissue to induce local responses (34) 
and improve tumor responses (16). Ionizing radiation can 
also inhibit distant tumors after local radiation therapy, 
a   phenomenon known as the abscopal eff  ect. This pheno-
menon has been reported in various malignancies but remains 
Figure 4.  Ionizing radiation alters the MHC class I–associated 
peptide profi  le and immunological responses. (A) Mass spectrom-
etry profiles of double-charged peptides eluted from corresponding 
rpHPLC fractions from nonirradiated and irradiated cells as indicated. 
The peptides marked by an asterisk are observed in both profiles, 
whereas the arrow indicates peptide CGI-51 that is observed only in 
the peptide fraction after irradiation. (B) Peptide sequences from 
  proteins induced by γ-radiation as determined by MS and the corre-
sponding proteins. Note that all peptides contain the anchor residues 
for HLA-A1 (in bold). (C) Identification of CTLs recognizing HLA-A1 
tetramers containing irradiation-induced peptides. Flow cytometric 
analysis of human blood mononuclear cells gated on CD5+ and 
CD4−/CD19− TCRγδ− staining (leftmost panel) to determine the 
CTL population.JEM VOL. 203, May 15, 2006  1267
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a poorly understood event. After irradiation of a tumor, 
T cells are probably required to mediate distant tumor growth 
inhibition (35, 36). Our data on the eff  ect of γ-irradiation 
on MHC class I molecules provides an explanation for the 
  immune-mediated abscopal eff  ect.
We applied doses between 1–25 Gy, which is lower or 
comparable with doses received by patients, and observed 
that ionizing radiation induces a dose-dependent increase in 
MHC class I presentation in two phases (Fig. 6). The fi  rst 
phase represents peptides derived from existing proteins, be-
cause inhibition of translation does not aff  ect the generation 
of these peptides. More polyubiquitinated proteins for prote-
asomal degradation are observed swiftly after radiation even 
at doses of 1–4 Gy, resulting in more peptides for MHC class I 
antigen presentation and enhanced MHC class I expression as 
peptides are the limiting step in complex formation (37). Ir-
radiation will result in the formation of free radicals even at 
low doses, and proteins will be modifi  ed directly by radiation 
or indirectly by radicals formed after water radiolysis, result-
ing in oxidation of various amino acids. These modifi  cations 
may target the aff  ected proteins for rapid degradation by the 
proteasome. Although this will refl  ect a small fraction of the 
cellular protein pool, it still raises the amount of peptides and 
thus MHC class I expression. In the second phase, the mTOR 
kinase is activated resulting in enhanced protein synthesis. As 
a result, more proteins are generated of which a fraction is 
immediately degraded as RDPs, resulting in increased intra-
cellular peptide levels. MHC class I molecules are better 
translated after mTOR activation, but no additional increase 
in MHC class I translation is observed. In addition, a substan-
tial pool of free MHC class I H chains is still observed even 
when cells are exposed to 20 Gy radiation, suggesting that 
more MHC class I molecules could have been loaded with 
peptide, if around. Because peptides are the limiting factor in 
MHC class I assembly (37), an increased peptide pool would 
Figure 5.  Irradiation of tumor cells boosts the effi  cacy of CTL in 
vitro and in vivo. MC38 cells were treated with (A) buffer, (B) 20 Gy radia-
tion, (C) rapamycin, or (D) radiation and rapamycin and recultured. After 24 h, 
the MHC levels were analyzed by fl  ow cytometry. (A–D) The dashed line 
depicts isotype control antibody; the solid line depicts H2-Kb. Inset numbers 
depict the percentage of positive cells (mean fl  uorescent intensity). (E) 111In-
labeled MC38 cells treated with buffer (□), 20 Gy radiation (●), rapamycin 
(○), or the combination of radiation and rapamycin (▲). After 24 h, the cells 
were cultured with different numbers of gp70-specifi  c CTL for 18 h. (F) Tem-
poral effects of H-2Kb expression after radiation. MC38 cells were exposed 
to various doses of radiation followed by culture for the times indicated. The 
surface expression of H2-Kb was subsequently determined by FACS analyses 
and the MFI plotted after being related to the MFI of H2-Kb expression of 
control MC38 cells. (G) C57BL/6 mice were injected with 3 × 105 MC38 
tumor cells s.c., and the volume of the tumor (in mm) was measured daily 
and plotted. (First panel) Mice receiving no additional treatment. (Second 
panel) Tumors in mice were subjected to external-beam irradiation (10 Gy) 
in situ on day 9 of tumor transplant (▲). (Third panel) Mice were adoptively 
transferred (IV) with 3 × 106 gp70-specifi  c CTL at day 10 (△). (Fourth panel) 
Tumors in mice were subjected to external-beam irradiation (10 Gy) in situ 
at day 9 (▲) followed by adoptive transfer of gp70-specifi  c CTL at day 10 (△). 
The number of mice in each arm of the experiment and the number of mice 
without any detectable tumor is indicated in the fi  gure.
Figure 6.  A model summarizing the three effects of ionizing 
  radiation on MHC class I antigen presentation. The early effects are 
caused by the degradation of proteins that may be triggered or damaged 
by irradiation. Later effects are caused by activation of the mTOR path-
way, which results in increased protein translation of proteins, and an 
increased generation of peptides from (the RDPs of) these new proteins. 
The increased peptide pool will enhance MHC class I assembly because 
peptides are the limiting factor. In addition, unique proteins will be ex-
pressed/up-regulated in response to ionizing radiation, resulting in novel 
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be most important for increased MHC class I expression. The 
data suggest that mTOR-increased “general” translation 
rather than specifi  c increases in MHC class I translation are 
important for the radiation-increased surface MHC class I 
expression, as observed by FACS. In addition to these two 
responses, irradiated cells also respond by expressing unique 
proteins, and peptides from these proteins are subsequently 
loaded by MHC class I molecules. Various proteins may be 
selectively up-regulated and/or degraded in response to radi-
ation, including DNA repair proteins like PCNA, MSH2, 
and MSH6, but also proteins involved in cell cycle check-
points, apoptosis, and protein degradation (11). Fragments of 
these proteins are found on MHC class I after irradiation. 
Our experimental protocol did not allow quantitation of the 
total peptide pool given the many experimental steps be-
tween MHC class I peptide isolation, peptide elution, con-
centration, and HPLC fractionation before MS analysis 
(which is also not a quantitative technique). Although the in-
put peptides should have been two- to threefold more in the 
irradiation pool (based on FACS analysis for surface MHC 
class I peptide combination), this diff  erence may be lost after 
the various procedures. Still, it is conceivable that mTOR 
activation results in altered protein synthesis and thus peptide 
profi  le. The MHC class I antigen presentation pathway is ex-
traordinary ineffi   cient, generating a threshold for self-anti-
gens that may only be presented after strong up-regulation. 
The resulting self-peptides are presented on irradiated tissue 
and may be recognized by specifi  c CTLs in the patient. We 
have identifi  ed such CTLs in blood after labeling with tetra-
mers loaded with three identifi  ed radiation-specifi  c self-pep-
tides, but these CTLs could not be expanded and stimulated 
ex vivo. Possibly, these CTLs are present in an anergic state. 
Because IFN-γ is locally secreted in response to irradiation 
(33, 34), such CTL may undergo further activation in irradi-
ated tissue. Specifi  c vaccination protocols may be required to 
reawaken these anergic CTLs, as has recently been described 
for successful in vivo antitumor responses (28), before the 
  local induction of the peptides by irradiation.
An alternative strategy to combine radiotherapy and im-
munotherapy is to apply local irradiation to increase expression 
of MHC class I molecules, as shown here in kidneys of locally 
irradiated HLA-A2 transgenic mice. Radiation-induced in-
crease in MHC class I levels leads to enhanced susceptibility of 
tumor cells to lysis by CTL in vitro. Notably, we previously 
reported radiation-enhanced killing by CTL of fi  ve human 
colon carcinoma cell lines. Analysis of their surface antigens 
showed only class I up-regulation as the common denomina-
tor (16). In fact, we now show that activation of the mTOR 
pathway by radiation is critical for the radiation-enhanced 
CTL killing. We examined whether irradiation and immune 
cells can also work in concert in vivo. Neither radiation nor 
adoptive transfer of specifi  c CTL was curative in the mouse 
model. The combination of irradiation of the tumor and adop-
tive CTL transfer strongly reduced the tumor volume, and 
most mice receiving this combination therapy completely 
eradicated the tumor mass. This is probably not due only to 
up-regulation of MHC class I expression because mTOR 
  activation will have more general eff  ects on protein expression 
including up-regulation of Fas, ICAM-1 (38), and interferon 
expression (33, 34). Higher doses of radiation enhances MHC 
class I expression for days or even weeks. This may depend on 
cell proliferation. Slowly dividing cells may have a longer half-
life of MHC class I molecules explaining why the rapidly 
  dividing MelJuSo cells have a shorter radiation-induced 
  increase in MHC class I expression than MC-38 cells. Up-
  regulation of other proteins may be acting in concert with MHC 
class I molecules in the local induction of CTL responses.
This combination of therapies is based on the concept 
that targeted radiation strongly supports adoptive immuno-
therapy of cancer. The synergistic eff  ect of the combination 
of radiotherapy and immunotherapy may explain the earlier 
mentioned abscopal eff  ects, as the locally induced up-regula-
tion of particular tumor-related antigens in MHC class I may 
lift the expression of these antigens above the threshold level 
needed for the activation of CTL. Once activated, these 
T cells might recognize and assault distant tumors.
The eff  ect of radiation on MHC class I expression, by 
enhancing the intracellular peptide pool, may be used in a 
new combination of radiotherapy and immunotherapy that 
could be attractive in the treatment of radiation-resistant tu-
mors but also to selectively boost antitumor responses of acti-
vated or adoptively introduced tumor-specifi  c CTLs. CTLs 
may then recognize the unique radiation-induced antigenic 
peptides or enhanced tumor-related self-antigens resulting in 
better tumor responses. Because radiation can be locally ap-
plied to the tumor without touching surrounding tissue, the 
specifi  city of radiotherapy can be combined with the speci-
fi  city of immunotherapy, as shown in this study. This novel 
combination of radio-immunotherapy may add a new per-
spective to existing cancer treatments.
MATERIALS AND METHODS
Mice, constructs, cell lines, and antibodies
TAP1-GFP was made by fusing full-length TAP1 to EGFP (Clontech 
Laboratories) and stably transfected in the melanoma cell line MelJuSo as 
  described (1). MelJuSo cells expressing HLA-A2-GFP have been described 
(39). MelJuSo was DNA typed and expresses HLA-A1, -B8, -Cw7, -DR3, 
and -DQ2 (40). The murine colon adenocarcinoma cell line, MC38 
(H-2b), has been described previously (41). The H-2Kb–restricted, gp70-spe-
cifi  c CD8+ CTL line, designated gp70-CTL, was generated from C57BL/6 
as described (42), and recognizes the peptide epitope p15 (KSPWFTTL). The 
CTL lines were maintained by weekly in vitro stimulation with irradiated, 
syngeneic naive splenocytes in RPMI 1640 with fetal calf serum, supple-
mented with 10 IU/ml murine IL-2 (Boehringer Mannheim). The irradiated 
syngeneic splenocytes were pulsed with 1 μg/ml gp70 peptide for 1 h and 
then washed before culture with the CTL (43). For cytotoxicity assays and 
adoptive transfer, the CTL were recovered at day 6 of the stimulation cycle by 
centrifugation through a density gradient (LSM; Organon Teknika).
HLA-A2.1 transgenic mice (17) were a gift from F. Lemonier (Institute 
Pasteur, Paris, France) and maintained germ-free in the animal facility of the 
Netherlands Cancer Institute. For the radio-immunotherapy experiments, 
female C57BL/6 mice were obtained from the National Cancer Institute, 
Frederick Cancer Research Facility. Mice were housed and maintained 
  under pathogen-free conditions in micro-isolator cages until used for exper-
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The anti–human transferring mAb 66Ig10 (44), the anti–human MHC 
class I mAb W6/32 (45), the anti–human class I H-chain serum (13), the 
anti–human MHC class II mAb 1B5 (40), and rabbit anti-GFP serum (40) 
were used. Ubiquitin was detected with monoclonal FK2 (Stressgen). Mouse 
cell surface staining was performed with primary FITC-labeled mAb H-2Kb, 
purchased from PharMingen. Rabbit anti–human class I H-chain serum (46) 
was used for the immunostaining of the HLA-A2 transgenic mice. The mAb 
CD5-FITC, CD4-PE, CD19-PE, and TCRγδ-PE were obtained from 
Becton Dickinson.
Biochemistry
Western blot analysis. MelJuSo cells were irradiated at the indicated doses 
1 and 6 h before lysis. Where indicated, 10 μM MG132 was added to cells 
30 min before lyses. All cells were treated with 50 μM N-ethylmaleimide 
5 min before lysis to prevent postlyses deubiquitylation of substrate proteins. 
Cells were lysed in 1× reducing SDS sample buff  er, boiled, and analyzed by 
10% SDS-PAGE, followed by Western blotting onto polyvinylidene fl  ou-
ride membranes. Membranes were blocked and stained for multiubiquitin 
with the FK2 antibody. Western blots were quantifi  ed by luminescence de-
tection (MultiImage; Alpha Innotech Corp.).
Biosynthetic labeling. HLA-A2/GFP-expressing MelJuSo cells (39) were 
irradiated with 0, 10, or 20 Gy and cultured in the presence or absence of 
10 nM rapamycin for 6 h in IMDM supplemented with 8% FCS. Cells were 
subsequently labeled with 100 μCi 35S-methionine/cystein (added to the 
normal culture medium) for 1 h before lysis in NP-40–containing lysis mix-
ture. 5% of the lysate was used to quantify total protein input using Bradford 
assay (BioRad Laboratories), and immunoprecipitates were isolated from 
equal amounts of total protein. MHC class I as well as class II complexes 
were isolated fi  rst with mAb W6/32 and 1B5 followed by isolation of the 
free MHC class I H chains, and samples were analyzed by 10% SDS-PAGE. 
A normal serum control was included. Gels were quantifi  ed by phosphoim-
age analysis (Fuji fi  lm FLA-3000).
Ionizing radiation
Cells were exposed to γ-irradiation from a 137Cs source. The indicated doses 
were given at a rate of 0.75 Gy per min. HLA-A2 transgenic mice were 
  locally exposed to 25 Gy γ-radiation. Therefore, the mice were maintained in
a leaden tube with holes during radiation, and the areas of radiation were in-
dicated on the skin with black ink (47). The mice were killed 24 h after irra-
diation, and tissues from the radiated and nonradiated areas were isolated and 
fi  xed in formalin for immunocytochemistry. Sections were cut and incubated 
with rabbit anti–human HLA class I H chain serum that recognizes HLA class I 
molecules under these conditions (46). In addition, no cross-contamination 
occurred using rabbit antibodies for staining mouse tissue. A second goat 
anti–rabbit Ig coupled to the far-red dye Cy5 (Molecular Probes) was used to 
minimize detection of tissue autofl  uorescence. Images were made by the 
Leica SP2 confocal system using the glow-over/glow-under mode, and 
quantifi  cation of fl  uorescence was performed using standard Leica software. 
Background (secondary antibody only) fl  uorescence was subtracted to deter-
mine the increase in HLA-A2 expression after ionizing radiation.
FACS and confocal fl  uorescence microscopy analysis 
for FRAP experiments
MelJuSo cells were stably transfected with a construct expressing EGFP in 
pcDNA3. Cells were exposed to 0 or 25 Gy radiation in the presence or ab-
sence of 20 nM rapamycin and cultured for the times indicated. Alterna-
tively, MelJuSo cells were γ-irradiated with 0–25 Gy and cultured for the 
indicated time spans in the presence or absence of 20 nM rapamycin, fol-
lowed by staining the MHC class I complexes with W6/32 and fl  ow cytom-
etry. For long-term experiments, MelJuSo or MC38 cells were exposed to 
1–25 Gy radiation and cultured for up to 7 d (MelJuSo) before quantitation 
of MHC class I expression by W6/32 and FACS analyses (gated on the living 
cell population only). Cells were seeded such that they did not require dilu-
tion (replating) during the culture period. MC38 cells were cultured for 11 d 
after radiation. MC38 cells were treated with 20 Gy and cultured for 24 h in 
the presence or absence of 20 nM rapamycin, followed by staining with 
FITC-labeled mAb H-2Kb and fl  ow cytometry.
Confocal analysis of living cells and FRAP experiments were performed 
as described previously (1). To inhibit proteasomes, cells were incubated at 
37°C in the presence of 10 μM lactacystin for 30 min. For ATP depletion, 
cells were incubated for 30 min with a mixture of NaAz (0.05%) and 2-de-
oxyglucose (50 μM). Diff  usion of TAP-GFP was determined as described 
(1). In brief, a circular spot in the ER was bleached at full laser intensity, and 
an attenuated laser beam was used to monitor recovery of fl  uorescence in the 
bleached region (using Leica TCS time-lapse). The half-time for recovery 
was calculated from each recovery curve after correction for loss of fl  uores-
cence caused by imaging (which was usually less than 4%). The diff  usion 
  coeffi     cient D was determined from at least three independent FRAP
experiments (generally at least 10 measurements per experiment) and de-
picted as mean value ± SD. As a standard, FRAP experiments of nonmanip-
ulated cells were included as internal control. Temperature in the culture 
chamber at the CLSM was 37°C and continuously controlled.
Peptide degradation
Internally quenched peptides were introduced by microinjection in con-
trol MelJuSo cells or irradiated MelJuSo cells (1–2 h after receiving a dose 
of 25 Gy), whereas fl  uorescence emission was detected as described (4). 
The peptide sequences were T[K-dabcyl]NKTER[C-fl  uorescein]Y 
(9-mer), T[K-dabcyl]NKTER[C-fl  uorescein]YFKDLGP  (15-mer),  and 
T[K-dabcyl]NKTER[C-fl  uorescein]Y  F  K  D  L  G  P  F  K  D  L  G  P  F  K  D  L  G  P   (27-mer). 
Peptides were HPLC purifi  ed and sequence verifi  ed by MS.
MHC class I peptide isolation, rpHPLC, MS, 
and peptide sequencing
MHC class I–peptide complexes were purifi  ed from >1010 MelJuSo cells 
that were either control cells or cells harvested 18 h after γ-irradiation with 
a dose of 25 Gy. Peptides were purifi  ed by affi   nity chromatography using 
anti–class I W6/32 antibodies. Peptides were eluted with TFA from the iso-
lated MHC class I molecules and passed through a 10-kD fi  lter as described 
(22). The resulting peptide pool was separated by RP-HPLC on a SMART 
system equipped with a reversed phase C18 column (Pharmacia Biotech) us-
ing an acetonitrile gradient in 0.1% TFA as previously described (48). Partial 
RP-HPLC profi  les were obtained from the respective class I eluates of con-
trol or irradiated cells. Aliquots were sampled from each HPLC fraction and 
analyzed by electrospray MS on a Q-TOF mass spectrometer (Micromass) as 
previously described (49). After comparison of the corresponding fractions, 
peptides unique to the irradiated cell fraction were subjected to tandem MS 
(approximate collision energy 25–30V). Amino acid sequences were interac-
tively interpreted with the program PeptideSearch (50).
Identifi  cation of specifi  c CTL with tetramers
PBMCs isolated from a buff  ycoat preparation of healthy donor blood were 
thawed and incubated with 10 μg/ml DNase I in Iscoves medium contain-
ing 8% FCS for 1 h at room temperature. Tetramers were generated by re-
folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), 
and F-box protein Fbl7(335–362) and human β2m as described (51). 106 PBMCs 
were incubated with APC-conjugated HLA-A1 tetramers for 10 min at 
37°C, washed, and incubated on ice with anti-CD5–FITC antibody, anti-
CD4–PE, anti-CD19–PE, and anti-TCRγδ . PE antibodies for 20 min. Cells 
were washed and analyzed by fl  ow cytometry (FACScalibur). Dead cells 
were excluded from analysis after detection with propidium iodide. The 
population of cells gated on CD5+ and CD4−, CD19−, TCRγδ− staining 
consisted of 93% CD8+ T lymphocytes (Fig. 4 C, R3). The percentage of 
cells that bind the respective tetramers was determined in this population.
CTL recognition
MC38 cells were exposed to 20 Gy radiation, 20 nM rapamycin (maintained 
throughout the 24 h culture), or a combination of radiation and rapamycin, 
and recultured for 24 h. These cells were used as targets in a standard cyto-
toxicity assay using 111In. These radiolabeled cells (1 × 103 cells/well) were 
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100:1 to 3.125:1 in 96-well U-bottomed plates (Costar) and cocultured for 
18 h at 37°C with 5% CO2. After incubation, supernatants were collected 
using a Supernatant Collection System (Skantron), and radioactivity was 
quantitated using a γ-counter (Cobra Autogamma; Packard). The percent-
age of specifi  c release of  111In was determined by the standard equation: 
% specifi  c lysis = ([experimental–spontaneous]/[maximum–spontaneous]) 
× 100. The nonspecifi  c lysis ranged between 6–11% for all groups.
Tumor therapy studies
C57BL/6 mice were injected with 3 × 105 MC38 tumor cells s.c. in the 
quadriceps area of the right hind-limb. 9 d after tumor transplant, tumors 
were irradiated with 10 Gy. The mice were restrained in a customized jig 
and placed in a leaded holder such that only the tumor was exposed to 
the irradiation beam. The irradiation was performed using a Pantax ma-
chine at 300 kV, 10 mA, and a dose rate of 157 cGy/min. The dose used 
(10 Gy) was predetermined to have a minimal eff  ect on the tumors s.c. 
growth rate.
24 h after tumor irradiation, a subset of mice received 3 × 106 gp70-
specifi  c CTLs i.v. by adoptive transfer. Tumor size was measured daily 
by digital caliper in two dimensions, and the volumes were calculated. 
Animals were killed when any tumor measurement (length or width) 
  exceeded 20 mm. The animals were housed and maintained in accor-
dance with the guidelines of the National Cancer Institute Animal Care 
and Use Committee and the Guide for the Care and Use of Laboratory Ani-
mals (Department of Health and Human Services Publication National 
Institutes of Health 85–23).
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